Olmetec and Bronchiectasis - a phase IV clinical study of FDA data

Summary:

Bronchiectasis is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 60+ old, also take Spiriva, and have Osteoporosis.

The phase IV clinical study analyzes which people have Bronchiectasis when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Bronchiectasis?

Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection) is found to be associated with 783 drugs and 858 conditions by eHealthMe. Check the latest studies of Bronchiectasis.

On Jul, 14, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 14 people (0.18%) have Bronchiectasis.

Among these 14 people:

What is the gender of people who have Bronchiectasis when taking Olmetec? *

female: 7.69 %
male: 92.31 %

What is the age of people who have Bronchiectasis when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Bronchiectasis? *

Sleep Apnea Syndrome: 14 people, 100.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 14 people, 100.00%
Dyspnea (difficult or laboured breathing): 14 people, 100.00%
Productive Cough: 14 people, 100.00%
Diastolic Dysfunction: 14 people, 100.00%
Wheezing (a high-pitched whistling sound made while you breath): 13 people, 92.86%
Depression: 13 people, 92.86%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 13 people, 92.86%
Fatigue (feeling of tiredness): 13 people, 92.86%
Enlarged Prostate: 13 people, 92.86%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Bronchiectasis?

- Check whether Bronchiectasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Bronchiectasis treatments and more:

Bronchiectasis (12,460 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchiectasis:

Bronchiectasis (783 drugs)

Browse all the conditions that are associated with Bronchiectasis:

Bronchiectasis (858 conditions)

Related publications that referenced our studies

Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, Lee SM, Yoon HI, Yim JJ, Yoo CG, Chung HS, "Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis", The International Journal of Tuberculosis and Lung Disease, 2014 Mar .
Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, Lee SM, Yoon HI, Yim JJ, Yoo CG, Chung HS, "Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis", The International Journal of Tuberculosis and Lung Disease, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.